Affiliation:
1. Department of Pharmaceutics, Indo Soviet Friendship College of Pharmacy, GT Road (NH-95), Ghal Kalan, Moga, Punjab,
142001, India
Abstract
Abstract:
Approximately 2% to 3% of men and 6% to 7% of women suffer from severe depressive
disorders. The existing drugs only partially relieve symptoms for roughly 40% of these patients. The
majority of antidepressant drugs are based on theories that are now 50 to 60 years old, and the sector is
in critical need of new drug development targets. In the recent decade, numerous genes have been
connected to depression in animal models, and serious depression does run in families in humans, indicating
both a genetic and environmental component. Depression has been linked to the malfunctioning
of serotonin signaling genes, including p11, SERT, etc, according to earlier research. Gene therapy
for depression has been found in some instances to be relatively safe, despite the fact that it may seem
riskier and more invasive than medication. Hence, there is a growing field regarding the safest delivery
mechanisms of these genes that treat major depressive disorders permanently. Hence, the present
review summarized the delivery mechanisms of various genes responsible for depressive disorders
along with their molecular mechanisms and delivery at the cellular level.
Publisher
Bentham Science Publishers Ltd.
Subject
Genetics (clinical),Drug Discovery,Genetics,Molecular Biology,Molecular Medicine